HTML Issue

Volume 12 Issue 4 ( October-December ) 2023

Original Articles

A Retrospective Study Of Pegaspargase In Pediatric Patients With Acute Lymphoblastic Leukemia
Dr. Krishna Chaitanya Puligundla, Dr. Firhanariuzina, Dr. Anjani Devi Musnipalli Dr .Pallavi Madhusudan Jaju, Dr. Anudeep Rao Padakanti, Dr. Kushala Reddy, Dr. Rajashekar Reddy, Dr. Radhika Parimkayala, Dr. Vishal Toka

Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous hematological disease, constituting 75-80% of leukemia in children. L-asparaginase is a key component of the standard induction therapy for pediatric ALL. The present study aimed to evaluate the clinical profile of pegylated Escherichia coli asparaginase (pegaspargase) in terms of treatment-related side effects in pediatric patients with ALL. Methods: This retrospective study included pediatric patients with ALL who were treated at the Pediatric Hemato-Oncology Center in Hyderabad from Jan 2019 to Dec 2022. The medical records of patients aged 18 years and below, with a diagnosis and treatment for ALL, were accessed. Patients treated with intramuscular/intravenous pegaspargase (2,500 IU/m2) for ALL were included in the study. Patient demographic characteristics and disease status were documented. The adverse events with the use of pegaspargase were also noted. Results: A total of 300 patients with ALL were included in the study. The majority of patients were aged <10 years (65.7%). Most of the patients were male (58%). B-cell ALL was the predominant immunophenotype in 253 patients. As per the National Cancer Institute (NCI) criteria, 192 patients had standard-risk ALL. Bacterial/fungal infection was the most common manifestation in 25.7% of patients. Allergic reactions were observed in 15% of patients. Thrombosis was noted in 19 patients, while 18 patients experienced fatigue. Other side effects included hypertension (n=13), hyperglycemia (n=11), and pancreatitis (n=8). Conclusion: Pegaspargase holds promise as a vital therapeutic agent in the treatment of pediatric ALL, with most adverse events being manageable and reversible.

 
Abstract View | Download PDF | Current Issue

Get In Touch

IJLBPR

322 Parlount Road Slough Berkshire SL3 8AX, UK

ijlbpr@gmail.com

Submit Article

© IJLBPR. All Rights Reserved.